InterveXion Therapeutics | Monoclonal Antibodies for Treatment of PCP & METH Abuse
InterveXion Therapeutics
InterveXion Therapeutics, based in Little Rock since 2004, is a drug discovery and development company focused on antibody-based therapies for treating human disease. We are developing monoclonal antibodies to treat substance abuse from PCP and methamphetamine. Abuse of these stimulants is increasing and no specific therapies are currently available for treatment.
InterveXion is developing PCP-mAb for the treatment of PCP abuse and METH-mAb for the treatment of methamphetamine abuse. These therapies are monoclonal antibodies that can "absorb" these toxins in the bloodstream to reduce the acute effects of overdose and can also be used in the chronic setting to help abusers overcome their dependency.
Latest News
-
NextGen Illumination Partners with Cherokee Nation for LED Manufacturing
NextGen Illumination of Fayetteville has partnered with Cherokee Nation Industries to manufacture its LED lighting products. The products will be manufactured in Stilwell, Okla., where Cherokee Nation Industries is headquartered.
-
Nexans AmerCable of El Dorado to Receive National Export Award
Nexans AmerCable is one of 57 recipients of the 2013 President's "E" Awards for exporting. Arkansas will recognize its own top exporters on May 22 at the 2013 Governor's Awards for Excellence in Global Trade.
-
A Look at Picasolar's Impressive 2013 Run
Picasolar is a University of Arkansas graduate-level startup which created a technology that improves solar cells. It's made an impressive run through the 2013 cycle of national business-plan competitions.
-
5 UA Startups on the Cusp of Big Things
Picasolar's 2013 successful run in national business-plan competitions is reminiscent of past University of Arkansas startups.
